HCPCS Differentiation Urged For Dermal Tissue Products, Biomaterials
This article was originally published in The Gray Sheet
Executive Summary
Regenerative tissue products would be reimbursed at the same level as less-expensive surgical supplies and biomaterials in physician offices if CMS upholds its preliminary HCPCS coding decisions